|

A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

RECRUITINGSponsored by The First Affiliated Hospital of Soochow University
Actively Recruiting
SponsorThe First Affiliated Hospital of Soochow University
Started2024-06-01
Est. completion2025-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06497452

Summary

The purpose of this study is to assess the efficacy and safety in the real-world settings of glofitamab in combination with salvage therapy among Chinese adult patients with relapsed or refractory B-cell non-hodgkin lymphoma.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Be diagnosed as B-NHL
* Relapse or refractory to previous treatment
* Participants who will be treated with glofitamab

Exclusion Criteria:

* Participant who currently participates in or with plan to participate in any interventional clinical trial
* Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.

Conditions2

B-Cell Non-Hodgkin LymphomaCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.